Emerging role of biologics for the treatment of melioidosis and glanders

References

• Currie BJ. Burkholderia pseudomallei and Burkholderia mallei: melioidosis and glanders. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. London (England): Churchill Livingstone; 2004. p. 2869–2879.
   Google Scholar
• Dvorak GD, Spickler AR. Glanders. J Am Vet Med Assoc. 2008;233:570–577.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Virk HS, Torres AG, et al. Melioidosis. Nat Rev Dis Prim. 2018;4:17107.
   PubMed Web of Science ®Google Scholar
• Galyov EE, Brett PJ, DeShazer D. Molecular insights into Burkholderia mallei and Burkholderia pseudomallei pathogenesis. Annu Rev Microbiol. 2010;64:495–517.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012;367:1035–1044.
   PubMed Web of Science ®Google Scholar
• Limmathurotsakul D, Golding N, Dance DAB, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016;1:1–5.
   Web of Science ®Google Scholar
• Khan I, Wieler LH, Melzer F, et al. Glanders in animals: a review on epidemiology, clinical presentation, diagnosis and countermeasures. Transbound Emerg Dis. 2013;60:204–221.
   PubMed Web of Science ®Google Scholar
• Khakhum N, Tapia D, Torres AG. Defense against biological attacks: burkholderia mallei and glanders. 2019. DOI:10.1007/978-3-030-03053-7
   Google Scholar
• Aschenbroich SA, Lafontaine ER, Hogan RJ. Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches. Expert Rev Vaccines. 2017;15:1163–1181.
   Web of Science ®Google Scholar
• Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med. 2015;36:111–125.
   PubMed Web of Science ®Google Scholar
• Estes DM, Dow SW, Schweizer HP, et al. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther. 2010. DOI:10.1586/eri.10.4
   PubMed Web of Science ®Google Scholar
• Morici L, Torres AG, Titball RW. Novel multi-component vaccine approaches for Burkholderia pseudomallei. Clin Exp Immunol. 2019;196:178–188. .
   PubMed Web of Science ®Google Scholar
• Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010. Emerg Infect Dis. 2012;18:e2.
   PubMedGoogle Scholar
• Saiprom N, Amornchai P, Wuthiekanun V, et al. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei from Thailand. Int J Antimicrob Agents. 2015;45:557–559.
   PubMed Web of Science ®Google Scholar
• Ross BN, Myers JN, Muruato LA, et al. Evaluating new compounds to treat Burkholderia pseudomallei infections. Front Cell Infect Microbiol. 2018;8:1–8.
   PubMed Web of Science ®Google Scholar
• Harris P, Engler C, Norton R. Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. Int J Antimicrob Agents. 2011;37:547–549.
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55:1162–1172.
   PubMed Web of Science ®Google Scholar
• Chaowagul W, Suputtamongkul Y, Smith MD, et al. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg. 1997;91:599–601.
   PubMed Web of Science ®Google Scholar
• Barnes KB, Hamblin KA, Richards MI, et al. Demonstrating the protective efficacy of the novel fluoroquinolone finafloxacin against an inhalational exposure to Burkholderia pseudomallei. Antimicrob Agents Chemother. 2017;61:1–17.
   Web of Science ®Google Scholar
• Chan E, Martelli P, Hui S, et al. In vitro susceptibility of ceftolozane-tazobactam against Burkholderia pseudomallei. Antimicrob Agents Chemother. 2018;6:1–2.
   Google Scholar
• Sengyee S, Saiprom N, Paksanont S, et al. Susceptibility of clinical isolates of burkholderia pseudomallei to a lipid a biosynthesis inhibitor. Am J Trop Med Hyg. 2017;97:62–67.
   PubMed Web of Science ®Google Scholar
• Bommineni GR, Kapilashrami K, Cummings JE, et al. Thiolactomycin-based inhibitors of bacterial β-ketoacyl-acp synthases with in vivo activity. J Med Chem. 2016;59:5377–5390.
   PubMed Web of Science ®Google Scholar
• Kreisberg JF, Ong NT, Krishna A, et al. Growth inhibition of pathogenic bacteria by sulfonylurea herbicides. Antimicrob Agents Chemother. 2013;57:1513–1517.
   PubMed Web of Science ®Google Scholar
• Cummings JE, Kingry LC, Rholl DA, et al. The Burkholderia pseudomallei enoyl-acyl carrier protein reductase fabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy. Antimicrob Agents Chemother. 2014;58:931–935.
   PubMed Web of Science ®Google Scholar
• Cummings JE, Beaupre AJ, Knudson SE, et al. Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei. Antimicrob Agents Chemother. 2014;58:1646–1651.
   PubMed Web of Science ®Google Scholar
• Laws TR, Taylor AW, Russell P, et al. The treatment of melioidosis: is there a role for repurposed drugs? A proposal and review. Expert Rev Anti Infect Ther. 2019;00:1–11.
   Google Scholar
• Mima T, Kvitko BH, Rholl DA, et al. In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents. 2011;38:157–159.
   PubMed Web of Science ®Google Scholar
• de Bandeira TJPG, Brilhante RSN, Rocha MFG, et al. In vitro antimicrobial susceptibility of clinical and environmental strains of Burkholderia pseudomallei from Brazil. Int J Antimicrob Agents. 2013;42:375–377.
   Web of Science ®Google Scholar
• Scarff JM, Waidyarachchi SL, Meyer CJ, et al. Aminomethyl spectinomycins: a novel antibacterial chemotype for biothreat pathogens. J Antibiot (Tokyo). 2019. DOI:10.1038/s41429-019-0194-8.
   PubMed Web of Science ®Google Scholar
• Barnes KB, Steward J, Thwaite JE, et al. Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders. Int J Antimicrob Agents. 2013;41:552–557.
   PubMed Web of Science ®Google Scholar
• Siritongsuk P, Hongsing N, Thammawithan S, et al. Two-phase bactericidal mechanism of silver nanoparticles against Burkholderia Pseudomallei. PLoS One. 2016;11:1–22.
   Web of Science ®Google Scholar
• Ruiz SI, El-Gendy N, Bowen LE, et al. Formulation and characterization of nanocluster ceftazidime for the treatment of acute pulmonary melioidosis. J Pharm Sci. 2016;105:3399–3408.
   PubMed Web of Science ®Google Scholar
• Ruiz SI, Bowen LE, Bailey MM, et al. Pulmonary delivery of ceftazidime for the treatment of melioidosis in a murine model. Mol Pharm. 2018;15:1371–1376.
   PubMedGoogle Scholar
• Castelo-Branco DSCM, Riello GB, Vasconcelos DC, et al. Farnesol increases the susceptibility of Burkholderia pseudomallei biofilm to antimicrobials used to treat melioidosis. J Appl Microbiol. 2016;120:600–606.
   PubMed Web of Science ®Google Scholar
• Koh GCKW, Limmathurotsakul D. Gamma interferon supplementation for melioidosis. Antimicrob Agents Chemother. 2010;54:4520.
   PubMed Web of Science ®Google Scholar
• Propst KL, Troyer RM, Kellihan LM, et al. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob Agents Chemother. 2010;54:1785–1792.
   PubMed Web of Science ®Google Scholar
• Waag DM. Efficacy of postexposure therapy against glanders in mice. Antimicrob Agents Chemother. 2015;59:2236–2241.
   PubMed Web of Science ®Google Scholar
• Khakhum N, Bharaj P, Myers JN, et al. Burkholderia pseudomallei tonB hcp1 live attenuated vaccine strain elicits full protective immunity against aerosolized melioidosis infection. mSphere. 2019;4:1–13.
   Web of Science ®Google Scholar
• Hatcher CL, Mott TM, Muruato LA, et al. Burkholderia mallei CLH001 attenuated vaccine strain is immunogenic and protects against acute respiratory glanders. Infect Immun. 2016. DOI:10.1128/IAI.00328-16
   Web of Science ®Google Scholar
• Marchetti R, Dillon MJ, Burtnick MN, et al. Burkholderia pseudomallei capsular polysaccharide recognition by a monoclonal antibody reveals key details toward a biodefense vaccine and diagnostics against melioidosis. ACS Chem Biol. 2015;10:2295–2302.
   PubMed Web of Science ®Google Scholar
• AuCoin DP, Reed DE, Marlenee NL, et al. Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei. PLoS One. 2012;7:e35386.
   PubMed Web of Science ®Google Scholar
• Peddayelachagiri BV, Paul S, Makam SS, et al. Functional characterization and evaluation of in vitro protective efficacy of murine monoclonal antibodies BURK24 and BURK37 against Burkholderia pseudomallei. PLoS One. 2014. DOI:10.1371/journal.pone.0090930
   PubMedGoogle Scholar
• Ceballos-Olvera I, Sahoo M, Miller MA, et al. Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1β is deleterious. PLoS Pathog. 2011;7:e1002452.
   PubMed Web of Science ®Google Scholar
• Weehuizen TAF, Lankelma JM, De Jong HK, et al. Therapeutic administration of a monoclonal anti-IL-1β antibody protects against experimental melioidosis. Shock. 2016;46:566–574.
   PubMed Web of Science ®Google Scholar
• Zhang S, Feng S-H, Li B, et al. In vitro and in vivo studies of monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei. Clin Vaccine Immunol. 2011;18:825–834.
   PubMed Web of Science ®Google Scholar
• Kim HY, Tsai S, Lo SC, et al. Production and characterization of chimeric monoclonal antibodies against Burkholderia pseudomallei and B. mallei using the DHFR expression system. PLoS One. 2011;6:1–14.
   Web of Science ®Google Scholar
• Zimmerman SM, Dyke JS, Jelesijevic TP, et al. Antibodies against in vivo-expressed antigens are sufficient to protect against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei. Infect Immun. 2017;85:1–25.
   Web of Science ®Google Scholar
• Easton A, Haque A, Chu K, et al. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis. 2011;204:636–644.
   PubMed Web of Science ®Google Scholar
• Judy BM, Taylor K, Deeraksa A, et al. Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis. PLoS One. 2012;7. DOI:10.1371/journal.pone.0034176
   Web of Science ®Google Scholar
• Puangpetch A, Anderson R, Huang YY, et al. Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei Infection in BALB/c mice. Clin Vaccine Immunol. 2012;19:675–683.
   PubMed Web of Science ®Google Scholar
• Puangpetch A, Anderson R, Huang YY, et al. Comparison of the protective effects of killed Burkholderia pseudomallei and CpG oligodeoxynucleotide against live challenge. Vaccine. 2014;32:5983–5988.
   PubMed Web of Science ®Google Scholar
• Koh GCKW, Maude RR, Schreiber MF, et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis. 2011;52:717–725.
   PubMed Web of Science ®Google Scholar
• Becq F, Verrier B, Rubartelli A, et al. Interleukin-1b secretion is impaired by inhibitors of the atp binding cassette transporter, ABC1. Rapid Commun. 1997;90:2911–2915.
   Google Scholar
• Koh GCKW, Weehuizen TA, Breitbach K, et al. Glyburide reduces bacterial dissemination in a mouse model of melioidosis. PLoS Negl Trop Dis. 2013. DOI:10.1371/journal.pntd.0002500
   PubMed Web of Science ®Google Scholar
• Wilson WJ, Afzali MF, Cummings JE, et al. Immune modulation as an effective adjunct post-exposure therapeutic for B. pseudomallei. PLoS Negl Trop Dis. 2016;10:1–15.
   Web of Science ®Google Scholar
• Asakrah S, Nieves W, Mahdi Z, et al. Post-exposure therapeutic efficacy of COX-2 inhibition against Burkholderia pseudomallei. PLoS Negl Trop Dis. 2013;7:1–10.
   Web of Science ®Google Scholar
• Skyberg JA, Rollins MCF, Holderness JS, et al. Nasal acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei infections. PLoS Pathog. 2012;8. DOI:10.1371/journal.ppat.1002587
   PubMed Web of Science ®Google Scholar
• Cortés-Vieyra R, Bravo-Patiño A, Valdez-Alarcón JJ, et al. Role of glycogen synthase kinase-3 beta in the inflammatory response caused by bacterial pathogens. J Inflamm (United Kingdom). 2012;9:1–9.
   Google Scholar
• Tay TF, Maheran M, Too SL, et al. Glycogen synthase kinase-3b inhibition improved survivability of mice infected with Burkholderia pseudomallei. Trop Biomed. 2012;29:551–567.
   PubMed Web of Science ®Google Scholar
• Maniam P, Nurul Aiezzah Z, Mohamed R, et al. Regulatory role of GSK3β in the activation of NF-κB and modulation of cytokine levels in Burkholderia pseudomallei-infected PBMC isolated from streptozotocininduced diabetic animals. Trop Biomed. 2015;32:36–48.
   PubMed Web of Science ®Google Scholar
• Alam S, Javor S, Degardin M, et al. Structure-based design and synthesis of a small molecule that exhibits anti-inflammatory activity by inhibition of myd88-mediated signaling to bacterial toxin exposure. Chem Biol Drug Des. 2015;86:200–209.
   PubMed Web of Science ®Google Scholar
• Mahlapuu M, Håkansson J, Ringstad L, et al. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6:1–12.
   PubMed Web of Science ®Google Scholar
• Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003;3:710–720.
   PubMed Web of Science ®Google Scholar
• Madhongsa K, Pasan S, Phophetleb O, et al. Antimicrobial action of the cyclic peptide bactenecin on Burkholderia pseudomallei correlates with efficient membrane permeabilization. PLoS Negl Trop Dis. 2013;7:1–13.
   Web of Science ®Google Scholar
• Abdelbaqi S, Deslouches B, Steckbeck J, et al. Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis and Burkholderia pseudomallei. J Med Microbiol. 2016;65:188–194.
   PubMed Web of Science ®Google Scholar
• Samy RP, Thwin MM, Stiles BG, et al. Novel phospholipase A2 inhibitors from python serum are potent peptide antibiotics. Biochimie. 2015;111:30–44.
   PubMed Web of Science ®Google Scholar
• Salmond GPC, Fineran PC. A century of the phage: past, present and future. Nat Publ Gr. 2015;13:777–786.
   Google Scholar
• Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol. 2004;2:166–173.
   PubMed Web of Science ®Google Scholar
• Yordpratum U, Tattawasart U, Wongratanacheewin S, et al. Novel lytic bacteriophages from soil that lyse Burkholderia pseudomallei. FEMS Microbiol Lett. 2011;314:81–88.
   PubMed Web of Science ®Google Scholar
• Kulsuwan R, Wongratanacheewin S, Wongratanacheewin RS, et al. Lytic capability of bacteriophages (family myoviridae) on Burkholderia pseudomallei. Southeast Asian J Trop Med Public Health. 2015;45:1344–1353.
   Web of Science ®Google Scholar
• Khakhum N, Yordpratum U, Boonmee A, et al. Identification of the Burkholderia pseudomallei bacteriophage ST79 lysis gene cassette. J Appl Microbiol. 2016;121:364–372.
   PubMed Web of Science ®Google Scholar
• Kvitko BH, Cox CR, Deshazer D, et al. X216, a P2-like bacteriophage with broad Burkholderia pseudomallei and B. mallei strain infectivity. BMC Microbiol. 2012;12:289.
   PubMed Web of Science ®Google Scholar
• Guang-Han O, Leang-Chung C, Vellasamy KM, et al. Experimental phage therapy for Burkholderia pseudomallei infection. PLoS One. 2016;11:1–16.
   Web of Science ®Google Scholar
• Kamjumphol W, Chareonsudjai P, Chareonsudjai S. Antibacterial activity of chitosan against Burkholderia pseudomallei. Microbiologyopen. 2018;7:1–8.
   Web of Science ®Google Scholar
• Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25:730–733.
   PubMed Web of Science ®Google Scholar